J&J
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Through the acquisition, AbbVie will gain Aliada's lead asset, a beta-amyloid-targeting drug in a Phase I trial designed to cross the blood-brain barrier.
Nucleome Therapeutics Collaborating With J&J to Identify Target Genes in Autoimmune Diseases
The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.
The drugmaker met increased demand following approval of Carvykti in earlier lines of therapy with expanded production at US and European facilities.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Janssen Pharma to Make CHF 24.6M Milestone Payment to AC Immune Tied to Anti-Tau Alzheimer's Trial
Janssen aims to enroll about 500 participants with presymptomatic Alzheimer's into the Phase IIb ReTain trial testing JNJ-2056.